14.step 1 Relapsed otherwise Refractory Diffuse Higher B-phone Lymphoma
The top removal pathways out-of SG3199 haven’t been learned within the people. SG3199 is expected getting minimally renally excreted.
No medically tall variations in the fresh pharmacokinetics off loncastuximab tesirine-lpyl have been seen according to age (20-94 age), gender, battle (Light against. Black), weight (42.step 1 so you’re able to 160.5 kg), ECOG updates (0 so you’re able to dos) otherwise light so you can reasonable kidney disability (CLcr 31 to Clients with Hepatic Impairment
Lightweight hepatic impairment (full bilirubin ? ULN and you will AST > ULN, or total bilirubin >step one to just one.5 ? ULN and you may one AST) could raise the exposure regarding unconjugated SG3199, not there clearly was zero clinically tall effect on loncastuximab tesirine-lpyl pharmacokinetics. The effect away from reasonable (total bilirubin >step 1.5 to help you ?step three ? ULN and one AST) or major (total bilirubin >step 3 ULN and you will one AST) hepatic disability for the loncastuximab tesirine-lpyl pharmacokinetics try not familiar.
Cytochrome P450 (CYP) Enzymes: SG3199 will not prevent CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4/5 at the medically relevant unconjugated SG3199 density.
Transporter Assistance: SG3199 is actually good substrate of P-glycoprotein (P-gp), although not a great substrate off breast cancer opposition protein (BCRP), normal anion-moving polypeptide (OATP)1B1, or all-natural cation transporter (OCT)step 1. Leia mais